These data thus indicate that CD73, either in a soluble form and in a T-cell membrane-bound form, by producing adenosine could potentially counteract the clinical efficacy of PD-1 blockade, reinforcing the therapeutic potential of targeting adenosine signalling pathway to improve the efficacy of immunotherapeutic agents in cancer patients. This evidence concerns the gene NT5E and cancer.